A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).

Shunsuke KagawaAtsushi MuraokaTakeshi KambaraHiroshi NakayamaRyosuke HamanoNorimitsu TanakaKazuhiro NomaKohji TanakayaHiroyuki KishimotoKunitoshi ShigeyasuShinji KurodaSatoru KikuchiKazuya KuwadaMasahiko NishizakiYasuhiro ShirakawaToshiyoshi Fujiwara

Published in: Cancer chemotherapy and pharmacology (2017)

Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive GC.

Keyphrases

phase ii study
locally advanced
neoadjuvant chemotherapy
epidermal growth factor receptor
rectal cancer
open label
squamous cell carcinoma
metastatic breast cancer
radiation therapy
randomized controlled trial
clinical trial
mass spectrometry
gas chromatography